**Oxymatrine inhibits non–small cell lung cancer via suppression of EGFR signaling pathway**

**Wei Li¹,²,³,⁴,ᵃ, Xinfang Yu⁵,ᵃ, Shiming Tan⁶, Wenbin Liu⁷, Li Zhou⁸ & Haidan Liu¹,²**

¹Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China  
²Clinical Center for Gene Diagnosis and Therapy, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China  
³Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China  
⁴Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China  
⁵Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA  
⁶Department of Hemopathology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China  
⁷Department of Pathology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China  
⁸Department of Pathology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, China

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

**Keywords**  
Akt, cyclin D1, epidermal growth factor receptor, non–small cell lung cancer, oxymatrine

**Correspondence**  
Haidan Liu, Department of Cardiovascular Surgery, Clinical Center for Gene Diagnosis and Therapy, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China. Tel: 8673185292178; Fax: 8673185292133; Email: lhd1129@csu.edu.cn

**Abstract**  
Epidermal growth factor receptor (EGFR) plays a crucial role in human non–small cell lung cancer (NSCLC) tumorigenesis. In this study, oxymatrine was identified as an EGFR signaling pathway inhibitor in NSCLC. Oxymatrine inhibited anchorage-dependent and independent growth of NSCLC cell lines but had no cytotoxicity in normal lung cells. We found that exposure to oxymatrine not only suppressed the activity of wild-type EGFR but also inhibited the activation of exon 19 deletion and L858R/T790M mutated EGFR. Flow cytometry analysis suggested that oxymatrine-induced cell cycle G0/G1 arrest was dependent on EGFR-Akt signaling. Exogenous overexpression of Myr-Akt rescued cyclin D1 expression in HCC827 cells. Moreover, oxymatrine prominently suppressed tumor growth in a xenograft mouse model. Thus, oxymatrine appears to be a novel therapeutic agent for NSCLC treatment.

**Introduction**  
Non–small cell lung cancer (NSCLC) is one of the most lethal cancers worldwide for both men and women [1]. Although the early diagnosis was improved and the standard treatment was developed during the past few decades, NSCLC is often diagnosed at an advanced stage, and the overall 5-year survival rate remains less than 15% [2–4]. Numerous evidence revealed that host genetic susceptibility is closely linked to increased NSCLC risk [5]. Overexpressed or hyperactivated of epidermal growth factor receptor (EGFR) is always detected in NSCLC. Recently, The EGFR targeting therapy has played a central role in advanced NSCLC treatment. Novel targeted therapeutic agents, including tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and osimertinib, or monoclonal antibody cetuximab, have been developed to interfere with EGFR signaling, and show promise in the treatment of advanced NSCLC [6–10].
Oxymatrine, one of the major alkaloid components found in the roots of Sophora species, have various pharmacological activities and are demonstrated to have anti-inflammatory, antiallergic, antiviral, antifibrotic, and cardiovascular protective effects [11]. Recent studies have demonstrated that oxymatrine has anticancer potentials in various human cancer cell lines, including breast cancer [12], gastric cancer [13], bladder cancer [14], hepatocellular carcinoma [15], colon cancer [16], ovarian cancer [17], and prostate cancer [18]. The molecular mechanism studies have demonstrated that induction of cell cycle arrest [19], promotion of apoptosis [14], inhibition of angiogenesis [20] and suppression of metastasis [17] were involved in oxymatrine-mediated antitumor effect. Nonetheless, the antitumor activity of oxymatrine in NSCLC, as well as its potential target was not clear.

In this study, the efficacy of oxymatrine against NSCLC was evaluated in vitro and in vivo. We discovered firstly that oxymatrine inhibited the activation of both wild-type and mutant EGFR. Our data revealed that oxymatrine-induced cell cycle arrest was mainly dependent on the suppression effect of EGFR-Akt-cyclin D1 signaling pathway.

Materials and Methods

Reagents and antibodies

Chemicals, including NaCl, Tris, SDS, and oxymatrine (>98%) were purchased from Sigma (St. Louis, MO), LY294002, PD98059, and Erlotinib were purchased from Selleck Chemicals (Houston, TX). The RPMI-1640 and fetal bovine serum (FBS) for cell culture were from Invitrogen (Grand Island, NY). Antibodies against p-EGFR (Tyr1068), EGFR, p-ERK1/2 (Thr202/Tyr204), p-Akt (Ser473), Akt1, Akt, ERK1/2, cyclin D1, cyclin A, cyclin E, CDK4, p21, CDK2, and p27 were obtained from Cell Signaling Technology, Inc. (Beverly, MA). Antibody against β-actin was from Sigma. Anti-Ki67 was from Abcam (Cambridge, MA).

Cell culture and transfection

Cells, including A549, H1975, HCC827, HBE, MRC5, and NL20 from American Type Culture Collection (ATCC, Manassas, VA) were cultured at 37°C in a humidified incubator with 5% CO₂, 5% CO₂, A549, H1975, and HCC827 were cultured in RPMI-1640 medium supplemented with 1% antibiotics and 10% FBS. The MRC5 lung fibroblast cell was cultured in Eagle’s Minimum Essential Medium supplemented with 1% antibiotics and 10% FBS. The HBE bronchus epithelial cell was grown in keratinocyte-serum-free medium with 0.05 mg/mL bovine pituitary extract, 5 ng/mL human recombinant EGF, 0.005 mg/mL insulin and supplemented with 500 ng/mL hydrocortisone. The NL20 bronchus epithelial cell was cultured in Ham’s F12 medium with 2.7 g/L glucose, 1.5 g/L sodium bicarbonate, 2.0 mmol/L L-glutamine, 0.005 mg/mL insulin, 0.1 mmol/L nonessential amino acids, 0.001 mg/mL transferrin, 10 ng/mL epidermal growth factor, 500 ng/mL hydrocortisone and supplemented with 4% FBS. The jetPEI (Qbiogene, Inc., Montreal, Canada) transfection reagent was used for transfection experiments. The cell lysate was extracted for Western blot analysis.

Immunoblotting

Nonidet P-40 buffer (50 mmol/L Tris-Cl, pH 8.0, 150 mmol/L NaCl, 0.5% Nonidet P-40, and protease inhibitor mixture) was used for protein extraction. After protein concentration, the denatured proteins (30 µg) were subject to sodium-dodecyl-sulfate–polyacrylamide gel electrophoresis and incubated with primary antibodies and an alkaline phosphatase (AP)-conjugated secondary antibody. Proteins were visualized by chemiluminescence (Amersham Biosciences, Piscataway, NJ).

MTS assay

The cells were counted and seeded (2 × 10⁵) into 96-well plates and incubated with oxymatrine as indicated. Cell proliferation was assessed by MTS assay (Promega, Madison, WI) according to the manufacturer’s protocol.

Anchorage-independent growth

The anchorage-independent growth assay was conducted as described previously [21]. Briefly, NSCLC cells were suspended (8000 cells/mL) in 1 mL of Eagle’s basal medium containing 0.3% agar, 1% antibiotics, 10% FBS, and different concentrations of oxymatrine. The mixture was then overlaid into six-well plates containing a 0.6% agar base and different concentrations of oxymatrine. The cells were maintained in an incubator for 1–2 weeks, the colonies were counted using the Image-Pro Plus software program (Media Cybernetics, Silver Spring, MD).

Flow cytometry

Flow cytometry assay was performed as described previously [22]. Briefly, the cells were treated with oxymatrine and suspended at a concentration of 1 × 10⁶ cells/mL. For apoptosis analysis, the cell suspension (300 µL) was incubated with 5 µL Annexin V and 3 µL propidium iodide in the dark for 10–15 min at room temperature, the apoptotic cells were quantified using a FACSort Flow Cytometer (BD, San Jose, CA). For cell cycle analysis,
the cells were collected and washed with ice-cold PBS for two times. After centrifuge, the cells were fixed in 70% ethanol overnight at 4°C. The cells were suspended in the staining solution containing 50 μg/mL propidium iodide and 0.1% ribonuclease A (RNase A) for 30 min at room temperature. Cell cycle was analyzed by Flow Cytometry.

**In vivo tumor growth**

The *in vivo* animal study was approved by the Animal Ethics Committee of Central South University. HCC827 cells (1 × 10⁶/100 μL) was counted and suspended in RPMI-1640 medium, then the cell suspension was inoculated s.c. into the right flank of 5-week-old female athymic nude mice. When average tumor volume reached around 50 mm³, an i.p. injection of oxymatrine at a dose of 50 mg/kg was initiated and repeated every 3 days. The control group was administered vehicle. The tumor volume was recorded by Vernier caliper and calculated following the formula of A × B² × 0.5. A is the longest diameter of tumor, B is the shortest diameter and B² is B squared.

**Immunohistochemical analysis of tumor tissue**

Immunohistochemical (IHC) staining was performed as described previously [23]. Briefly, the slide was baked at 60°C for 2 h. After deparaffinization and rehydration, the slide was submerged into boiling sodium citrate buffer (10 mmol/L, pH 6.0) for 10 min, and incubated with 3% H₂O₂ for 10 min at room temperature. 50% goat serum albumin in 1 × PBS was used for blocking. Then the slide was incubated with a primary antibody in a humidified chamber at 4°C overnight. The slide was washed with ice-cold PBS and hybridized with the secondary antibody for 1 h at room temperature. Hematoxylin was used for counterstaining. The intensity was viewed by Image-Pro PLUS (v.6) software programs.

**Statistical analysis**

The quantitative data were expressed as mean values ± SD of at least three independent experiments. Significant differences were determined by Student’s *t*-test, *P* < 0.05 was considered statistical significance.

**Results**

**Oxymatrine inhibits NSCLC cell growth**

Oxymatrine (Fig. 1A, MW. 264.36) has shown antitumor activities against several types of human cancers. In order to identify the antitumor effect of oxymatrine on NSCLC, we first investigated whether oxymatrine exerts any cytotoxic effect on normal human lung cells. HBE, MRC-5, and NL20 cells were treated with various concentrations of oxymatrine for 24 h. Data are shown as means ± SD from triplicate experiments.

**Oxymatrine suppresses the EGFR signaling pathway**

EGFR signaling pathway plays a crucial role in lung tumorigenesis. We then determined whether oxymatrine had any effect on EGFR activation. We chose three NSCLC cell lines, including the A549, H1975, and HCC827 cells, which harbor the WT EGFR, L858R/T790M, and Exon 19 deletion mutations, respectively. Immunoblotting analysis indicated that the phosphorylation of EGFR was decreased in response to oxymatrine treatment in these three cell lines, which suggested that oxymatrine can effectively inhibit the activation of both WT and activating mutations of EGFR (Fig. 3A). Moreover, we also found
that the activation of EGFR downstream target genes, such as Akt and ERK1/2, were substantially suppressed after oxymatrine treatment (Fig. 3A). Further study showed that oxymatrine treatment strikingly inhibited EGF-induced EGFR, Akt, and ERK1/2 activation in HCC827 cells (Fig. 3B and C). These results suggest that oxymatrine suppresses the EGFR signaling pathway.

**Oxymatrine induces G0/G1 cell cycle arrest and decreases cyclin D1**

We next tested the effect of oxymatrine on cell cycle progression in HCC827 cells. After exposure to 60 or 120 µmol/L oxymatrine for 24 h, the cell proportion of G0/G1 phase were reached around 50% or 60%
Oxymatrine inhibits EGFR signaling

W. Li et al.

Oxymatrine inhibits EGFR signaling in HCC827 cells. Additionally, the cells in S phase were decreased from 50% to 40%. This result suggested the inhibition or delay in DNA replication/synthesis and cell proliferation. The Western blotting data showed that oxymatrine dramatically decreased the expression of cyclin D1, but did not downregulate the protein levels of cyclin A and cyclin E. Moreover, the CDK inhibitors, including p21 and p27, were increased in oxymatrine-treated groups (Fig. 4B). The Flow Cytometry results showed that oxymatrine did not markedly induce apoptosis even at the relatively higher concentration of 120 μmol/L (Fig. 4C). These results indicate that oxymatrine-mediated HCC827 cell growth inhibition may partly dependent on G0/G1 cell cycle arrest.

Akt inhibition is required for oxymatrine-mediated cell cycle arrest in HCC827 cells

Our results demonstrated that oxymatrine inhibited human NSCLC cells growth and EGFR signaling pathway activation. In order to further determine that oxymatrine-induced inhibition of cell cycle progression is dependent on the suppression of EGFR signaling pathway, we selectively inhibited EGFR, Akt, and ERK1/2 kinase activity via small-molecule inhibitors in HCC827 cells. Our results indicated that suppression of EGFR activation by oxymatrine and EGFR inhibitor, erlotinib, resulted in downregulation of cyclin D expression. Furthermore, the Akt inhibitor, LY294002, dramatically decreased cyclin D1 expression in HCC827 cells (Fig. 5A). However, downregulation of ERK1/2 phosphorylation had no obvious effect on cyclin D1 expression (Fig. 5A). We further found that overexpression of constitutively activated Akt1 (myr-Akt1) rescued the cyclin D1 expression in oxymatrine-treated HCC827 cells (Fig. 5B). Additionally, the flow cytometry data indicated that myr-Akt1 transfection rescued oxymatrine-induced cell cycle arrest in HCC827 cells, overexpression of myr-Akt1 increased the cell proportion of S phase (Fig. 5C). Our data suggest that oxymatrine-regulated G0/G1 cell cycle arrest is partly dependent on Akt activation modulation.
Oxymatrine inhibits in vivo tumor growth

We further determined the antitumor effects of oxymatrine on NSCLC cells in a xenograft mouse model. HCC827 cells were transplanted into the right flank of 6-week-old female athymic nude mice. Oxymatrine (50 mg/kg per day) or vehicle treatment was initiated when the average tumor volume reached ≥50 mm³. Results indicated that the final average tumor volume of the vehicle-treated group was around 752.02 ± 146.76 mm³, whereas average tumor size of the oxymatrine-treated group was 479.92 ± 91.89 mm³ (Fig. 6A and B). The average tumor weights of the vehicle-treated group and oxymatrine-treated group were 0.77 ± 0.08 g and 0.47 ± 0.05 g, respectively (Fig. 6C). During the treatment period, oxymatrine did not affect body weight of the mice (Fig. 6D). IHC analysis showed that oxymatrine substantially inhibited the phosphorylation of EGFR in HCC827 xenograft tumors. Moreover, the protein level of Ki67 was decreased in oxymatrine-treated group (Fig. 6E). Our results indicate that oxymatrine inhibits tumor growth in vivo.
Discussion

Increased levels of EGFR gene expression are observed in human cancers. Previous studies have reported that EGFR was overexpressed in 62% of NSCLC cases, and its high expression is correlated with a poor prognosis [24, 25]. More importantly, EGFR mutations have been identified in approximately 10–30% of NSCLC [26]. The most common mutations are in-frame deletions of exon 19 and the L858R point mutation in exon 21, which result in hyperactivation of EGFR signaling pathway [27]. Since EGFR plays a crucial role in NSCLC, the EGFR-targeted therapeutics currently represents the best-studied example of oncogene addiction in human NSCLC. The tyrosine kinase inhibitors (EGFR-TKIs) of EGFR was designed, and this kind of small-molecule compounds reversibly or irreversibly bind to the ATP binding pocket of the mutated EGFR, thereby suppressing the phosphorylation of the EGFR signaling [28–30].

Although the clinical application of tyrosine kinase inhibitors, including gefitinib and erlotinib, have shown a dramatic prolong survival in NSCLC patients with EGFR activating mutations, most patients eventually develop acquired resistance [31]. The emergence of a secondary mutation, T790M, accounts for one-half of acquired resistance to TKIs, whereas approximately 20% of the acquired resistance cases are associated with the activation of ErbB3/PI3K/Akt signaling mediated by c-Met amplification [27, 32]. Thus, the second-generation TKIs, such as afatinib, and the 3rd generation TKIs, including osimertinib, have been developed [7, 33, 34]. However, the TKI resistance in human NSCLC has increased clinically. More importantly, only the activating mutation harbored patients respond to TKI treatment [35]. Thus, further discover novel therapeutic targets or develop new chemicals are still an urgent demand for clinical NSCLC treatment.

In this study, we reported firstly that the natural compound, oxymatrine, exerts an antitumor effect on NSCLC via directly inhibits the EGFR signaling (Fig. 3). The calculated IC50 (72 h) value of oxymatrine on A549, H1975, and HCC827 cells, which harbors the WT EGFR,
L858R/T790M, and Exon 19 deletion mutated EGFR, was around 145 μmol/L, 98 μmol/L, and 82 μmol/L, respectively (data not shown). Our results indicated that oxymatrine is much more inhibition effective on Exon 19 deletion mutated EGFR and L858R/T790M mutated EGFR than WT EGFR. The MTS results demonstrated that oxymatrine had no obvious cytotoxicity on normal lung cells at concentrations ≤ 240 μmol/L, but markedly inhibited NSCLC at concentrations ≥ 60 μmol/L. Importantly, the in vivo data showed that the consumption of oxymatrine did not induce significant body weight loss occurred in the oxymatrine-treated group (Fig. 6). These results suggested that oxymatrine inhibited NSCLC via targeting EGFR signaling but has no obvious cytotoxicity on normal cells. Recently, Liu et al. found that oxymatrine synergistically enhances the antitumor activity of oxaliplatin in colon carcinoma [36] and enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo [15]. Thus, oxymatrine owns the potential to serve as a sensitizing agent for NSCLC treatment via combination with other drugs.

Deregulation of the cell cycle is one of the hallmarks of human cancer [37, 38]. Cyclin D1 plays a crucial role in the regulation of the cell cycle G1-S transition, and compelling evidences have demonstrated that cyclin D1 is frequently amplified and overexpressed in human NSCLS [39, 40]. Alterations of the pathways regulated by growth factors such as EGF, and by the ras oncogene product
may contribute to cyclin D1 expression [40]. Evidence from laboratory investigation discovered that inhibition of EGFR activity by TKIs dramatically suppressed the expression of cyclin D1 protein [41–43] in NSCLC. Here, we found that oxymatrine-mediated cyclin D1 downregulation was dependent on the suppression of EGFR-Akt signaling, exogenous overexpression of Myr-Akt rescued cyclin D1 expression in the oxymatrine-treated group (Figs. 4 and 5). However, inhibition of ERK1/2 had no obvious effect on cyclin D1 expression (Fig. 5A). Moreover, recent studies indicated that EGFR can translocate to the nucleus and act as a transcription factor or kinase in human cancers [44–46]. The anticancer treatment, such as radiation and EGFR-targeted therapy, or other stimuli, including ligand binding, substantially induced EGFR nuclear localization [46, 47]. The nuclear EGFR regulates gene expression, such as promotes cyclin D1 transcription [48, 49]. Although our results showed that oxymatrine-induced cyclin D1 downregulation was partly dependent on EGFR-Akt kinases activity, there is still a possibility that oxymatrine directly inhibited EGFR nuclear translocation and EGFR-mediated cyclin D1 transcription regulation.

Overall, our data implied that suppression of EGFR signaling pathway is involved in oxymatrine-induced tumor inhibition in NSCLC. We analyzed the suppression effect of oxymatrine against WT EGFR, exon 19 deletion and the L858R/T790M mutated EGFR in vitro. For the first time, we identified that decreases the activity of the EGFR-Akt-cyclin D1 signaling pathway was one of the major underlying mechanisms for oxymatrine-induced cell cycle arrest in human NSCLC.

Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Siegel, R., D. Naishadham, and A. Jemal. 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11–30.
2. DeSantis, C. E., C. C. Lin, A. B. Mariotto, R. L. Siegel, K. D. Stein, J. L. Kramer, et al. 2014. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64:252–271.
3. Thomas, A., S. V. Liu, D. S. Subramaniam, and G. Giaccone. 2015. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12:511–526.
4. Rosell, R., and N. Karachaliou. 2015. Lung cancer in 2014: optimizing lung cancer treatment approaches. Nat. Rev. Clin. Oncol. 12:75–76.
5. Herbst, R. S., J. V. Heymach, and S. M. Lippman. 2008. Lung cancer. N. Engl. J. Med. 359:1367–1380.
6. Wang, Y., M. Wang, Q. Wang, Z. Geng, and M. Sun. 2017. Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 8:29406–29415.
7. Liao, B. C., C. C. Lin, J. H. Lee, and J. C. Yang. 2017. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer 110:7–13.
8. Liu, T. C., X. Jin, Y. Wang, and K. Wang. 2017. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am. J. Cancer Res. 7:187–202.
9. Castellanos, E., E. Feld, and L. Horn. 2017. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J. Thorac. Oncol. 12:612–623.
10. Normanno, N., M. R. Maiello, N. Chicchinelli, A. Iannaccone, C. Esposito, R. De Cecio, et al. 2017. Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opin. Ther. Targets 21:159–165.
11. Liu, Y., Y. Xu, W. Ji, X. Li, B. Sun, Q. Gao, et al. 2014. Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol. 35:5111–5119.
12. Lin, B., D. Li, and L. Zhang. 2016. Oxymatrine mediates Bax and Bcl-2 expression in human breast cancer MCF-7 cells. Pharmacie 71:154–157.
13. Guo, B., T. Zhang, J. Su, K. Wang, and X. Li. 2015. Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells. Cancer Chemother. Pharmacol. 75:353–363.
14. Li, S., Y. Zhang, Q. Liu, Q. Zhao, L. Xu, S. Huang, et al. 2017. Oxymatrine inhibits proliferation of human bladder cancer T24 cells by inducing apoptosis and cell cycle arrest. Oncol. Lett. 13:4453–4458.
15. Liu, Y., T. Bi, W. Dai, G. Wang, L. Qian, Q. Gao, et al. 2016. Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. Tumour Biol. 37:7589–7597.
16. Wang, X., C. Liu, J. Wang, Y. Fan, Z. Wang, and Y. Wang. 2017. Oxymatrine inhibits the migration of human colorectal carcinoma RKO cells via inhibition of PAI-1 and the TGF-beta1/Smad signaling pathway. Oncol. Rep. 37:747–753.
17. Li, J., K. Jiang, and F. Zhao. 2015. Oxymatrine suppresses proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating microRNA29b and downregulating matrix metalloproteinase2 expression. Mol. Med. Rep. 12:5369–5374.
18. Wu, C., W. Huang, Y. Guo, P. Xia, X. Sun, X. Pan, et al. 2015. Oxymatrine inhibits the proliferation of
prostate cancer cells in vitro and in vivo. Mol. Med. Rep. 11:4129–4134.

19. He, M., L. Jiang, B. Li, G. Wang, J. Wang, and Y. Fu. 2017. Oximotrine suppresses the growth and invasion of MG63 cells by up-regulating PTEN and promoting its nuclear translocation. Oncotarget 8:65100–65110.

20. Chen, H., J. Zhang, J. Luo, F. Lai, Z. Wang, H. Tong, et al. 2013. Antiangiogenic effects of oximotrine on pancreatic cancer by inhibition of the NF-kappaB-mediated VEGF signaling pathway. Oncol. Rep. 30:589–595.

21. Li, W., C. Peng, M. H. Lee, D. Lim, F. Zhu, Y. Fu, et al. 2013. TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 73:6938–6950.

22. Yu, X., W. Li, Q. Deng, S. You, H. Liu, S. Peng, et al. 2017. Neoalbconal inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Mol. Carcinog. 56:1414–1426.

23. Liu, H., W. Li, X. Yu, F. Gao, Z. Duan, X. Ma, et al. 2016. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Oncotarget 7:56338–56354.

24. Nicholson, R. I., J. M. Gee, and M. E. Harper. 2001. EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4):S9–S15.

25. Krause, D. S., and R. A. Van Etten. 2005. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353:172–187.

26. Cancer Genome Atlas Research. 2014. N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:534–550.

27. Sharma, S. V., D. W. Bell, J. Settleman, and D. A. Haber. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7:169–181.

28. Herbst, R. S., M. Fukuoka, and J. Baselga. 2004. Gefitinib—a novel targeted approach to treating cancer. Nat. Rev. Cancer 4:956–965.

29. Lamb, Y. N., and L. J. Scott. 2017. Osimertinib: a review in T790M-positive advanced non-small cell lung cancer. Target Oncol. 12:555–562.

30. Li, X., and C. Zhou. 2017. Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget. 2017 Jul 5. https://doi.org/10.18632/oncotarget.19007.

31. Jackman, D., W. Pao, G. J. Riely, J. A. Engelman, M. G. Kris, P. A. Janne, et al. 2010. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28:357–360.

32. Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043.

33. Proto, C., G. Lo Russo, G. Corrao, M. Ganzinelli, F. Facchinetti, R. Minari, et al. 2017. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori 103:325–337.

34. Ricciuti, B., S. Baglivo, L. Pagliaulunga, A. De Giglio, G. Bellezza, R. Chiar, et al. 2017. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther. Adv. Med. Oncol. 9:387–404.

35. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500.

36. Liu, Y., T. Bi, Z. Wang, G. Wu, L. Qian, Q. Gao, et al. 2016. Oximotrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway. Apoptosis 21:1398–1407.

37. Otto, T., and P. Sicinski. 2017. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17:93–115.

38. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144:646–674.

39. Gautschi, O., D. Ratschiller, M. Gugger, D. C. Betticher, and J. Heighway. 2007. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55:1–14.

40. Musgrove, E. A., C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland. 2011. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11:558–572.

41. Petty, W. J., K. H. Dragnev, V. A. Memoli, Y. Ma, N. B. Desai, A. Biddele, et al. 2004. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin. Cancer Res. 10:7547–7554.

42. Kalish, L. H., R. A. Kwong, I. E. Cole, R. M. Gallagher, R. L. Sutherland, and E. A. Musgrove. 2004. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 10:7764–7774.

43. Kobayashi, S., T. Shimamura, S. Monti, U. Steidl, C. J. Hetherington, A. M. Lowell, et al. 2006. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 66:11389–11398.

44. Li, H., L. You, J. Xie, H. Pan, and W. Han. 2017. The roles of subcellularly located EGFR in autophagy. Cell. Signal. 35:223–230.

45. Brand, T. M., M. Iida, N. Luthar, M. M. Starr, E. J. Huppert, and D. L. Wheeler. 2013. Nuclear EGFR as a
molecular target in cancer. Radiother. Oncol. 108:370–377.

46. Dittmann, K., C. Mayer, and H. P. Rodemann. 2010. Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther. Onkol. 186:1–6.

47. Han, W., and H. W. Lo. 2012. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318:124–134.

48. Lin, S. Y., K. Makino, W. Xia, A. Matin, Y. Wen, K. Y. Kwong, et al. 2001. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3:802–808.

49. Bazzani, L., S. Donnini, F. Finetti, G. Christofori, and M. Ziche. 2017. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells. Oncotarget 8:31270–31287.